UNSPSC 51401558: Loprazolam

This classification denotes a benzodiazepine with the molecular formula C23H21ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 759N8462G8, chemically known as 6-(2-chlorophenyl)-2,4-dihydro-2-((4-methyl-1-piperazinyl)methylene)-8-nitro-1h-imidazo(1,2-a) (1,4)benzodiazepin-1-one but generally known as loprazolam, which bears US NIH Compound Identifier 3033860. European Medicines Agency schedules Loprazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08576MIG.

UNSPSC 51401558 Loprazolam is a Commodity code that captures pharmaceutical procurement by state and local governments, though recent solicitations under this code span a broader range of pharmaceutical products and delivery systems than the code name alone suggests. State and local buyers are procuring naloxone and drug deactivation systems for public health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and exploring direct-to-manufacturer prescription programs to improve fulfillment efficiency and cost management. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing organizations serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, which includes Oregon participation). The procurement mix reflects a shift toward both emergency response pharmaceuticals and cost-management strategies, with vendors required to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and specific insurance requirements.

Recent activity concentrates in Florida, Texas, and Minnesota, with the cooperative purchasing vehicle extending reach across multiple states. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026, due July 26, 2023), requiring quarterly deliveries and fixed-fee pricing with a two-year initial term and one-year renewal option; the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026, due April 3, 2026), which is exploratory in nature and designed to inform future formal procurement strategy; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026), spanning multiple states with July 1, 2026 contract effectiveness and weighted evaluation favoring price competitiveness at 75 percent.